Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection

Autor: J.-C. Delchier, S. Bastuji-Garin, J. Raymond, F. Megraud, A. Amiot, E. Cambau, C. Burucoa, Samia Baloul, Thierry Barrioz, Geoffray Bizouard, Jacques Breuil, Gaelle Buzaglo, Ariane Chryssostalis, Lionel Deforges, Sylva Doumet, Xavier Dray, Isabelle Durand-Zaleski, Bijan Ghaleh, Florence Grattard, Philippe Le Corvoisier, Alain Mangeol, François Mion, Stéphane Nahon, Latifa Noussair, Isabelle Podglajen, Laurent Raskine, Chantal Roure-Sobas, Elia Samaha, Franck Zerbib

Publikováno v: Médecine et Maladies Infectieuses
Médecine et Maladies Infectieuses, Elsevier Masson, 2020, 50, pp.492-499. ⟨10.1016/j.medmal.2019.06.001⟩
Médecine et Maladies Infectieuses, 2020, 50, pp.492-499. ⟨10.1016/j.medmal.2019.06.001⟩

Introduction Resistance to clarithromycin and fluoroquinolones is increasing in many countries. We aimed to assess the efficacy of a tailored PCR-guided triple therapy versus an empirical triple therapy in the treatment of H. pylori infection. Patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6260cb39d8ba8d861da6fb8319a270ee
https://hal.archives-ouvertes.fr/hal-03477218